Abemaciclib联合芳香化酶i抑制剂治疗转移性HR+ HER2/ new阴性乳腺癌

D. Yukalchuk, D. M. Ponomarenko, T.N. Yukalchuk, S. S. Sidorova, A.V. Shevchuk, A. Novopashin, S. Prokopchuk, G.N. Tepikina
{"title":"Abemaciclib联合芳香化酶i抑制剂治疗转移性HR+ HER2/ new阴性乳腺癌","authors":"D. Yukalchuk, D. M. Ponomarenko, T.N. Yukalchuk, S. S. Sidorova, A.V. Shevchuk, A. Novopashin, S. Prokopchuk, G.N. Tepikina","doi":"10.33978/2307-3586-2022-18-13-18-23","DOIUrl":null,"url":null,"abstract":"The article presents a clinical case illustrating the effectiveness of abemaciclib in combination with anastrozole in metastatic estrogen receptor-positive HER2/neu-negative breast cancer (BC). CDK4/6 inhibitors have changed the paradigm of treatment of patients with hormone-positive HER2 metastatic BC. Thanks to the ability of palbociclib, ribociclib and abemaciclib to delay and overcome resistance to endocrine therapy, the effectiveness of treatment of patients not only with newly diagnosed disease, but also with endocrine – resistant, and taking into account the independent effectiveness of abemaciclib and chemorefractor BC has increased. The combination of aromatase inhibitors and abemaciclib is associated with an increase in the effectiveness of treatment in the most prognostically unfavorable contingent of patients.","PeriodicalId":11400,"journal":{"name":"Effective Pharmacotherapy","volume":"135 1","pages":""},"PeriodicalIF":0.0000,"publicationDate":"2022-04-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"The Use of Abemaciclib in Combination with Aromatase Iinhibitors in Metastatic HR+ HER2/Neu-Negative Breast Cancer\",\"authors\":\"D. Yukalchuk, D. M. Ponomarenko, T.N. Yukalchuk, S. S. Sidorova, A.V. Shevchuk, A. Novopashin, S. Prokopchuk, G.N. Tepikina\",\"doi\":\"10.33978/2307-3586-2022-18-13-18-23\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"The article presents a clinical case illustrating the effectiveness of abemaciclib in combination with anastrozole in metastatic estrogen receptor-positive HER2/neu-negative breast cancer (BC). CDK4/6 inhibitors have changed the paradigm of treatment of patients with hormone-positive HER2 metastatic BC. Thanks to the ability of palbociclib, ribociclib and abemaciclib to delay and overcome resistance to endocrine therapy, the effectiveness of treatment of patients not only with newly diagnosed disease, but also with endocrine – resistant, and taking into account the independent effectiveness of abemaciclib and chemorefractor BC has increased. The combination of aromatase inhibitors and abemaciclib is associated with an increase in the effectiveness of treatment in the most prognostically unfavorable contingent of patients.\",\"PeriodicalId\":11400,\"journal\":{\"name\":\"Effective Pharmacotherapy\",\"volume\":\"135 1\",\"pages\":\"\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2022-04-25\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Effective Pharmacotherapy\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.33978/2307-3586-2022-18-13-18-23\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Effective Pharmacotherapy","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.33978/2307-3586-2022-18-13-18-23","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0

摘要

本文报道了一个临床病例,说明阿贝马昔利联合阿那曲唑治疗转移性雌激素受体阳性HER2/新阴性乳腺癌(BC)的有效性。CDK4/6抑制剂已经改变了激素阳性HER2转移性BC患者的治疗模式。由于palbociclib、ribociclib和abemaciclib延缓和克服内分泌治疗耐药的能力,不仅对新诊断的疾病,而且对内分泌耐药的患者,考虑到abemaciclib和化疗抗癌药BC的独立有效性,治疗的有效性有所提高。芳香化酶抑制剂和abemaciclib联合使用可提高预后最不利的患者的治疗效果。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
The Use of Abemaciclib in Combination with Aromatase Iinhibitors in Metastatic HR+ HER2/Neu-Negative Breast Cancer
The article presents a clinical case illustrating the effectiveness of abemaciclib in combination with anastrozole in metastatic estrogen receptor-positive HER2/neu-negative breast cancer (BC). CDK4/6 inhibitors have changed the paradigm of treatment of patients with hormone-positive HER2 metastatic BC. Thanks to the ability of palbociclib, ribociclib and abemaciclib to delay and overcome resistance to endocrine therapy, the effectiveness of treatment of patients not only with newly diagnosed disease, but also with endocrine – resistant, and taking into account the independent effectiveness of abemaciclib and chemorefractor BC has increased. The combination of aromatase inhibitors and abemaciclib is associated with an increase in the effectiveness of treatment in the most prognostically unfavorable contingent of patients.
求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
自引率
0.00%
发文量
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信